Low bone mineral density is a common feature of Zellweger spectrum disorders

Eric T. Rush, Jennifer L. Goodwin, Nancy E. Braverman, William B Rizzo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Patients with Zellweger Spectrum Disorders (ZSDs) have impaired peroxisome biogenesis and severe, multisystem disease. Although the neurologic symptoms of ZSD tend to be the most prominent, patients also have hepatic, renal and adrenal impairment. Little is known about bone health in patients with ZSD, particularly those with mild or moderate presentation. We investigated 13 ZSD patients who had strikingly abnormal bone mineral density for age. DXA scans showed mean lumbar and femoral neck Z-scores of -. 3.2. There were no major differences between ambulatory and nonambulatory patients, and no biochemical abnormalities consistent with rickets or vitamin D deficiency were seen. Cyclic bisphosphonate therapy in one ZSD patient was successfully used to increase in bone mineral density. Although the etiology of bone disease in this condition is unknown, we speculate that altered signaling through the PPARγ pathway or deficient plasmalogens in patients with ZSD disrupts osteogenesis, resulting in poor bone formation and poor mineralization. Further investigation into the pathogenic mechanisms of bone disease in ZSD and the role of peroxisomal metabolism in osteogenesis may yield insights into the pathology of bone disease and suggest novel treatment options.

Original languageEnglish (US)
Pages (from-to)33-37
Number of pages5
JournalMolecular Genetics and Metabolism
Volume117
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Zellweger Syndrome
Bone Density
Minerals
Bone
Bone Diseases
Osteogenesis
Peroxisomal Disorders
Plasmalogens
Rickets
Peroxisome Proliferator-Activated Receptors
Vitamin D Deficiency
Peroxisomes
Femur Neck
Photon Absorptiometry
Diphosphonates
Pathology
Neurologic Manifestations
Metabolism
Vitamin D
Health

Keywords

  • Bisphosphonate
  • Bone densitometry
  • Bone mineral density
  • PPAR-gamma
  • Pathologic fracture
  • Peroxisomal biogenesis disorder
  • Zellweger spectrum disorder

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology

Cite this

Low bone mineral density is a common feature of Zellweger spectrum disorders. / Rush, Eric T.; Goodwin, Jennifer L.; Braverman, Nancy E.; Rizzo, William B.

In: Molecular Genetics and Metabolism, Vol. 117, No. 1, 01.01.2016, p. 33-37.

Research output: Contribution to journalArticle

Rush, Eric T. ; Goodwin, Jennifer L. ; Braverman, Nancy E. ; Rizzo, William B. / Low bone mineral density is a common feature of Zellweger spectrum disorders. In: Molecular Genetics and Metabolism. 2016 ; Vol. 117, No. 1. pp. 33-37.
@article{dd8ebb16194343ba8d6f8ee6d1cf9946,
title = "Low bone mineral density is a common feature of Zellweger spectrum disorders",
abstract = "Patients with Zellweger Spectrum Disorders (ZSDs) have impaired peroxisome biogenesis and severe, multisystem disease. Although the neurologic symptoms of ZSD tend to be the most prominent, patients also have hepatic, renal and adrenal impairment. Little is known about bone health in patients with ZSD, particularly those with mild or moderate presentation. We investigated 13 ZSD patients who had strikingly abnormal bone mineral density for age. DXA scans showed mean lumbar and femoral neck Z-scores of -. 3.2. There were no major differences between ambulatory and nonambulatory patients, and no biochemical abnormalities consistent with rickets or vitamin D deficiency were seen. Cyclic bisphosphonate therapy in one ZSD patient was successfully used to increase in bone mineral density. Although the etiology of bone disease in this condition is unknown, we speculate that altered signaling through the PPARγ pathway or deficient plasmalogens in patients with ZSD disrupts osteogenesis, resulting in poor bone formation and poor mineralization. Further investigation into the pathogenic mechanisms of bone disease in ZSD and the role of peroxisomal metabolism in osteogenesis may yield insights into the pathology of bone disease and suggest novel treatment options.",
keywords = "Bisphosphonate, Bone densitometry, Bone mineral density, PPAR-gamma, Pathologic fracture, Peroxisomal biogenesis disorder, Zellweger spectrum disorder",
author = "Rush, {Eric T.} and Goodwin, {Jennifer L.} and Braverman, {Nancy E.} and Rizzo, {William B}",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.ymgme.2015.11.009",
language = "English (US)",
volume = "117",
pages = "33--37",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Low bone mineral density is a common feature of Zellweger spectrum disorders

AU - Rush, Eric T.

AU - Goodwin, Jennifer L.

AU - Braverman, Nancy E.

AU - Rizzo, William B

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Patients with Zellweger Spectrum Disorders (ZSDs) have impaired peroxisome biogenesis and severe, multisystem disease. Although the neurologic symptoms of ZSD tend to be the most prominent, patients also have hepatic, renal and adrenal impairment. Little is known about bone health in patients with ZSD, particularly those with mild or moderate presentation. We investigated 13 ZSD patients who had strikingly abnormal bone mineral density for age. DXA scans showed mean lumbar and femoral neck Z-scores of -. 3.2. There were no major differences between ambulatory and nonambulatory patients, and no biochemical abnormalities consistent with rickets or vitamin D deficiency were seen. Cyclic bisphosphonate therapy in one ZSD patient was successfully used to increase in bone mineral density. Although the etiology of bone disease in this condition is unknown, we speculate that altered signaling through the PPARγ pathway or deficient plasmalogens in patients with ZSD disrupts osteogenesis, resulting in poor bone formation and poor mineralization. Further investigation into the pathogenic mechanisms of bone disease in ZSD and the role of peroxisomal metabolism in osteogenesis may yield insights into the pathology of bone disease and suggest novel treatment options.

AB - Patients with Zellweger Spectrum Disorders (ZSDs) have impaired peroxisome biogenesis and severe, multisystem disease. Although the neurologic symptoms of ZSD tend to be the most prominent, patients also have hepatic, renal and adrenal impairment. Little is known about bone health in patients with ZSD, particularly those with mild or moderate presentation. We investigated 13 ZSD patients who had strikingly abnormal bone mineral density for age. DXA scans showed mean lumbar and femoral neck Z-scores of -. 3.2. There were no major differences between ambulatory and nonambulatory patients, and no biochemical abnormalities consistent with rickets or vitamin D deficiency were seen. Cyclic bisphosphonate therapy in one ZSD patient was successfully used to increase in bone mineral density. Although the etiology of bone disease in this condition is unknown, we speculate that altered signaling through the PPARγ pathway or deficient plasmalogens in patients with ZSD disrupts osteogenesis, resulting in poor bone formation and poor mineralization. Further investigation into the pathogenic mechanisms of bone disease in ZSD and the role of peroxisomal metabolism in osteogenesis may yield insights into the pathology of bone disease and suggest novel treatment options.

KW - Bisphosphonate

KW - Bone densitometry

KW - Bone mineral density

KW - PPAR-gamma

KW - Pathologic fracture

KW - Peroxisomal biogenesis disorder

KW - Zellweger spectrum disorder

UR - http://www.scopus.com/inward/record.url?scp=84951851453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951851453&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2015.11.009

DO - 10.1016/j.ymgme.2015.11.009

M3 - Article

C2 - 26643206

AN - SCOPUS:84951851453

VL - 117

SP - 33

EP - 37

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 1

ER -